COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
YS Biopharma Co., Ltd.
PIKA COVID-19 vaccine
Phase 2 study of PIKA COVID-19 Vaccine met its primary endpoint- reported on Mar 27, 2023.

FDA cleared the IND application for PIKA COVID-19 vaccine for a Phase 1 study.
Jiangsu Recbio Technology Co., Ltd.
Emergency use authorization for ReCOV was received in Mongolia- reported on Mar 21, 2023.

Results from the Phase 2 study showed that neutralizing antibody titer levels against Omicron BF.7 and BA.2.75 induced by sequential vaccination of ReCOV were significantly better than those of the mRNA vaccine group- reported on Dec.25 2022.
Direct Biologics
Favorable safety, dosing and efficacy results from the Phase 2 study of ExoFlo in hospitalized COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) were reported on Mar.14, 2023.

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for ExoFlo for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19- reported on Apr. 12, 2022.
Dosing of patients in the Phase 1 study of DYAI-100 COVID-19 booster vaccine candidate was completed and no serious adverse events have been reported as on March 7, 2023.
Initial safety and antibody response update expected in Q2, 2023.
FDA declined the request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized COVID-19 patients who are at high risk for Acute Respiratory Distress Syndrome (ARDS).- reported on Mar.2, 2023.
Valneva SE
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued positive opinion for the use of VLA2001 in adults 18 to 50 years of age as a booster dose- reported on Feb.23, 2023.

Data showed that additional booster dose of VLA2001 in participants who were previously vaccinated with 2 or 3 doses of mRNA COVID-19 vaccine elicited only a marginally increased neutralizing antibody response- reported on Dec.30, 2022.

The search for treatments to battle the novel coronavirus (COVID-19) is an ongoing process. With the world on alert, pharmaceutical companies around the globe are rapidly developing drugs to help combat this deadly virus. This calendar tracks various Coronavirus Drug companies and COVID-19 Vaccine progress, and lists the companies currently working on drugs against COVID-19.

Understanding the Vaccine Development Process

Vaccines for Covid-19 are produced in a well-defined process. Steps typically include preclinical research, which includes basic studies to determine the safety and efficacy of a potential vaccine; phases 1, 2 and 3 of clinical trials, that involve increasing numbers of volunteers until ultimately large scale trials can confirm safety and efficacy; and finally regulatory review, manufacturing, and distribution. Each step requires specific resources, skills, infrastructure and time before the vaccine is made available to the public.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
German sportswear company Adidas AG said Wednesday it will withdraw its request to block the application by the Black Lives Matter movement to trademark a yellow three-stripe design similar to Adidas' branding. This move by Adidas comes just 48 hours after it had filed an objection to the U.S. Patent and Trademark Office against the use of the three parallel stripes design. Generative artificial intelligence or AI technologies, including the highly popular ChatGPT, could expose around 300 million full-time jobs around the world to automation, a report by Goldman Sachs predicts, deepening the rising fears about job security. According to a new research report by GS economists, "The Potentially Large Effects of Artificial Intelligence on Economic Growth",.. UBS Group AG has called back its former Chief Executive Officer Sergio Ermotti to lead the Swiss banking giant amid the new challenges and priorities it faces following its planned acquisition of troubled domestic rival Credit Suisse Group AG. Following the news, UBS shares were gaining more than 2 percent in Swiss trading as well as in pre-market activity on the NYSE.